Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

St. Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project(PCGP): Whole Genome Sequencing of Childhood Retinoblastoma

ABSTRACT: St. Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project(PCGP): Whole Genome Sequencing of Childhood Retinoblastoma

PROVIDER: PRJNA75313 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

St. Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project(PCGP): Whole Genome Sequencing of Childhood Medulloblastoma

Project description:St. Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project(PCGP): Whole Genome Sequencing of Childhood Medulloblastoma

| PRJNA75339 | ENA

St. Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project (PCGP): Whole Genome Sequencing of Core Binding Factor Acute Myeloid Leukemia

Project description:St. Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project (PCGP): Whole Genome Sequencing of Core Binding Factor Acute Myeloid Leukemia

| PRJNA75321 | ENA

St. Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project (PCGP): Somatic Mutations in Pediatric AML FAB-M7 Subtype by Whole Transcriptome Sequencing

Project description:St. Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project (PCGP): Somatic Mutations in Pediatric AML FAB-M7 Subtype by Whole Transcriptome Sequencing

| PRJNA75335 | ENA

St. Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project: Whole Genome Sequencing of Childhood Hypodiploid Acute Lymphoblastic Leukemia

Project description:St. Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project: Whole Genome Sequencing of Childhood Hypodiploid Acute Lymphoblastic Leukemia

| PRJNA74913 | ENA

Homo sapiens

Project description:St. Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project(PCGP): Whole Genome Sequencing of Childhood Retinoblastoma

| PRJNA75315 | ENA

Expression data for biophenotypic leukemia patients treated in St. Jude Children's Research Hospital

Project description:Mixed-lineage leukemias represent about 3-5% of acute leukemias occurring in patients of all ages and comprise several different subtypes (biphenotypic, bilineal, and lineage switch). The optimal therapeutic approach to these cases, especially in pediatric patients, has not been defined. We used microarrays to detail the gene expression of pediatric patients with biophenotypic leukemia. Keywords: Patient sample accumulation

2009-01-06 | GSE14286 | GEO

Retinoblastoma genome methylation data

Project description:Retinoblastoma is the most common intraocular cancer of infancy and childhood, with an incidence of one case per 15,000 - 20,000 live births. An early event in retinoblastoma genesis is a functional loss of both alleles of the RB1 gene. However, other genes are likely to be involved in the development of this cancer. In this study we sought to build a comprehensive molecular portrait of this cancer by performing transcriptomic, methylomic, genomic profiling of primary retinoblastoma samples. Most of the patients whose tumors were studied had received no treatment prior to surgical enucleation.

2021-07-06 | GSE58783 | GEO

Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital.

Project description:To characterize the biology and optimal therapy of acute mixed-lineage leukemia in children, we reviewed the pathologic and clinical features, including response to therapy, of 35 patients with mixed-lineage leukemia. The majority of cases (91%) had blasts cells that simultaneously expressed either T-lineage plus myeloid markers (T/myeloid, n = 20) or B-lineage plus myeloid markers (B/myeloid, n = 12). Overall survival rates for the B/myeloid and T/myeloid subgroups were not significantly different from each other or from the rate for acute myeloid leukemia (AML) but were inferior to the outcome in children with acute lymphoblastic leukemia (ALL). Patients who failed to achieve complete remission with AML-directed therapy could often be induced with a regimen of prednisone, vincristine, and L-asparaginase. Analysis of gene-expression patterns identified a subset of biphenotypic leukemias that did not cluster with T-cell ALL, B-progenitor ALL, or AML. We propose that treatment for biphenotypic leukemia begin with one course of AML-type induction therapy, with a provision for a switch to lymphoid-type induction therapy with a glucocorticoid, vincristine, and L-asparaginase if the patient responds poorly. We also suggest that hematopoietic stem cell transplantation is often not required for cure of these patients.

| S-EPMC2686179 | biostudies-literature

Trial design: The St. Jude Children's Research Hospital Cancer Survivors Tobacco Quit Line study.

Project description:Nearly, one-fifth of childhood cancer survivors (CCSs) smoke cigarettes. Because CCSs are already at greater medical smoking-related risks, targeting them for smoking cessation efforts is a high priority. One of the major challenges with smoking cessation in CCSs is how to reach such a geographically dispersed population. This study aims to demonstrate that these challenges can be overcome through the use of telephone-based tobacco quit lines (QLs). This report describes the design of the St. Jude Cancer Survivor Tobacco QL study, which is a randomized controlled clinical trial that will examine the long-term (1-year) efficacy of a counselor initiated vs. participant initiated tobacco QL with adjunctive nicotine replacement therapy (NRT) in both groups. Participants (N=950) will be recruited nationally and randomly assigned to one of the two interventions. The counselor initiated intervention includes six scheduled telephone sessions of a behavioral intervention and provision of 8 weeks of NRT. The participant initiated intervention allows the participant to call the QL at their convenience, but includes the same six telephone sessions and provision of 2 weeks of NRT. Both groups will receive two follow-up phone calls at 8 weeks and 1 year after enrollment to assess their smoking status. The primary outcome measure is cotinine-validated self-reported smoking abstinence at 1-year follow-up. Results from this study will provide the first evidence about the efficacy of intensive QL cessation intervention in this high-risk population. Such evidence can lead as well to the dissemination of this intervention to other medically compromised populations.

| S-EPMC2818168 | biostudies-literature

Retinoblastoma genome variation profiling by genome tiling array

2021-07-06 | GSE58784 | GEO